Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues.
Spilios ManolakopoulosΗarikleia KranidiotiAnastasia KourikouMelanie-Maria DeutschChristos TriantosChrysostomos TsoliasEmanuel K ManesisNicoletta MathouAlexandra AlexopoulouEmilia HadziyannisGeorgios PapatheodoridisPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
Our study supports that NA therapy can be safely stopped in non-cirrhotic patients with HBeAg-negative CHB. Over a median follow-up of more than 5 years, half of the patients remained without retreatment with a substantial proportion of them achieving functional cure.